Αρχική World News First Global Estimates of Cervical Cancer Attributable to HIV

First Global Estimates of Cervical Cancer Attributable to HIV

Women living with HIV have a six-fold higher risk of developing cervical cancer compared with women without HIV infection. In view of this increased risk, it was estimated that nearly 5% of all cervical cancer cases worldwide are attributable to HIV infection. This attributable fraction varies greatly by region and is highest in countries where coverage of human papillomavirus (HPV) vaccination, and of cervical cancer screening and treatment for all women and girls, is suboptimal. 

Dr Shona Dalal of the World Health Organization (WHO) and colleagues performed a systematic literature search and meta-analysis of five databases to identify studies analysing the association between HIV infection and cervical cancer. They published their findings on 16 November 2020 in The Lancet Global Health

Geographical disparities in the cervical cancer burden reflect the availability, coverage, and quality of preventive strategies and the prevalence of risk factors. Nearly nine in ten women who die from cervical cancer live in low-income and middle-income countries. Besides infection with high-risk HPV, other known risk factors include smoking, increased parity, and infection with HIV; HIV enhances HPV-induced carcinogenesis. 

Cervical cancer is the most frequently detected cancer in women living with HIV and is classified as an AIDS-defining illness. Although high-burden settings for cervical cancer and HIV overlap, the extent of the contribution of HIV to the burden of cervical cancer and the proportion of cervical cancer cases due to co-infection with HIV have yet to be quantified, the authors wrote in the study background. 

In this meta-analysis and modelling study, the investigators aimed to provide a pooled estimate of the relative risk for cervical cancer among women living with HIV in Africa, Asia, Europe, and North America and present the estimated number of cases of cervical cancer among women living with HIV and attributable to HIV, based on UNAIDS HIV prevalence and GLOBOCAN 2018 cancer estimates for 2018. 

In 24 studies that have met inclusion criteria, there were 236 127 included women with HIV. The pooled risk of cervical cancer was increased in women living with HIV (risk ratio [RR] 6.07, 95% confidence interval [CI] 4.40–8.37). Globally, 5.8% (95% CI 4.6–7.3) of new cervical cancer cases in 2018 (33 000 new cases, 95% CI 26 000–42 000) were diagnosed in women living with HIV and 4.9% (95% CI 3.6–6.4) were attributable to HIV infection (28 000 new cases, 20 000–36 000). 

The most affected regions were southern Africa and eastern Africa. In southern Africa, 63.8% (95% CI 58.9–68.1) of women with cervical cancer (9200 new cases, 95% CI 8500–9800) were living with HIV, as were 27.4% (23.7–31.7) of women in eastern Africa (14 000 new cases, 12 000–17 000). 

Age-standardised incidence rates of HIV-attributable cervical cancer were more than 20 per 100 000 in six countries, all in southern Africa and eastern Africa. 

The authors concluded that it is important to improve access to cervical cancer prevention for all women in all settings, but particularly in countries where access to health services is difficult and HIV prevalence is high. Focusing on both cervical cancer prevention and HIV prevention, including integration of cervical cancer screening and treatment with HIV services, can optimise benefits. Such an approach in countries with the highest burden of HIV-attributable cervical cancer will contribute substantially to delivering on the WHO 2030 targets of 90% coverage of vaccination of girls, 70% coverage of screening, and 90% coverage of treatment leading to elimination of cervical cancer as a major public health problem. 

The study was funded by the WHO, US Agency for International Development, and US President’s Emergency Plan for AIDS Relief. 

Reference 

Stelzle D, Tanaka LF, Ken Lee K, et al. Estimates of the global burden of cervical cancer associated with HIV. Lancet Glob Health; Published Online 16 November 2020. DOI: https://doi.org/10.1016/ S2214-109X(20)30459-9.

Source

NEWSLETTER

Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like
57ΑκόλουθοιΑκολουθήστε

Διαβαστε Επίσης

ΠΑΓΚΟΣΜΙΑ ΗΜΕΡΑ ΚΑΡΚΙΝΟΥ

Η Παγκόσμια Ημέρα Κατά του Καρκίνου καθιερώθηκε με πρωτοβουλία της Διεθνούς Ένωσης κατά του Καρκίνου (UICC), που εκπροσωπεί 800 οργανώσεις σε 155 χώρες του...

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ)

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...

Καρκίνος: Ευεργετική για τους καρκινοπαθείς η άσκηση

Σημαντικά ωφέλη προσφέρει η άσκηση, ακόμη και σε ασθενείς με καρκίνο. Οι περισσότεροι ασθενείς αγνοούν τα οφέλη που μπορεί να έχει γι’ αυτούς η συχνή...
- Advertisment -

Ροή Ειδήσεων

Final Results of the Collaborative EORTC/Intergroup Randomised Phase III Study of Adjuvant Imatinib in Localised GIST

Final analysis of the EORTC Soft Tissue and Bone Sarcoma Group, the Australasian Gastro-Intestinal Trials Group, UNICANCER, French Sarcoma Group, Italian Sarcoma Group, and...

Pink Van Makes the Rounds Throughout Rural New Zealand to Offer Free Breast Health Advice

Many of us have questions about breast cancer prevention or screenings. Getting lost in a Google rabbit hole can sometimes be overwhelming and could...

How My Inherited Cancer Diagnosis Has Made Me a Better Oncologist

Dr. Lewis is Director of Gastrointestinal Oncology at Intermountain Healthcare Utah; Vice President of American Multiple Endocrine Neoplasia Support; Head of the Communications Committee...

FDA Approves Cemiplimab-rwlc for Advanced Non-Small Cell Lung Cancer With High PD-L1 Expression

On 22 February 2021, the US Food and Drug Administration (FDA) approved cemiplimab-rwlc (Libtayo, Regeneron Pharmaceuticals, Inc.) for the first-line treatment of patients with...

Five-Year Outcomes with CAR T Cell Therapy

The results of 5-year follow-up in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma who were treated with CD19-directed,...

Countdown to 100,000 OncoLife Survivorship Care Plans: How it all started

In April of 2007, OncoLink launched the OncoLife Survivorship Care Plan, a tool to create care plans for people who have survived cancer. As...